| Literature DB >> 25814526 |
Yaozu Xiang1, Jijun Cheng2, Dandan Wang1, Xiaoyue Hu1, Yi Xie1, Jeremiah Stitham1, Gourg Atteya1, Jing Du1, Wai Ho Tang1, Seung Hee Lee1, Kristen Leslie1, Geralyn Spollett3, Zejian Liu3, Erica Herzog4, Raimund I Herzog3, Jun Lu2, Kathleen A Martin1, John Hwa1.
Abstract
An elevated level of von Willebrand factor (VWF) in diabetic patients is associated with increased risk of thrombotic cardiovascular events. The underlying mechanism of how VWF expression is upregulated in diabetes mellitus is poorly understood. We now report that hyperglycemia-induced repression of microRNA-24 (miR-24) increases VWF expression and secretion in diabetes mellitus. In diabetic patients and diabetic mouse models (streptozotocin/high-fat diet-induced and db/db mice), miR-24 is reduced in both tissues and plasma. Knockdown of miR-24 in mice leads to increased VWF mRNA and protein levels and enhanced platelet tethering (spontaneous thrombosis). miR-24 tightly controls VWF levels through pleiotropic effects, including direct binding to the 3' untranslated region of VWF and targeting FURIN and the histamine H1 receptor, known regulators of VWF processing and secretion in endothelial cells. We present a novel mechanism for miR-24 downregulation through hyperglycemia-induced activation of aldose reductase, reactive oxygen species, and c-Myc. These findings support a critical role for hyperglycemic repression of miR-24 in VWF-induced pathology. miR-24 represents a novel therapeutic target to prevent adverse thrombotic events in patients with diabetes mellitus.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25814526 PMCID: PMC4447857 DOI: 10.1182/blood-2015-01-620278
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113